Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $39.67

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ:KNSA) has received a consensus rating of "Buy" from six analysts, with an average 12-month price target of $39.67.
• The company's stock opened at $26.33, and has a market capitalization of $1.92 billion with a 12-month price range between $17.82 and $30.69.
• Kiniksa Pharmaceuticals reported a 72.5% year-over-year increase in quarterly revenue, totaling $137.79 million, and exceeded earnings expectations with an EPS of $0.11.

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) have received a consensus rating of "Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued a report on the stock in the last year is $41.17.

KNSA has been the subject of several recent research reports. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research report on Sunday, July 6th. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Finally, Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, insider Ross Moat sold 27,594 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total transaction of $800,777.88. Following the sale, the insider owned 9,415 shares in the company, valued at approximately $273,223.30. The trade was a 74.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Eben Tessari sold 18,900 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $28.72, for a total transaction of $542,808.00. Following the sale, the chief operating officer owned 49,163 shares in the company, valued at approximately $1,411,961.36. This trade represents a 27.77% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 344,215 shares of company stock valued at $9,840,484. Company insiders own 53.48% of the company's stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares in the last quarter. US Bancorp DE bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $33,000. Asset Management One Co. Ltd. bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $41,000. Wealthquest Corp bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $42,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at $61,000. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Trading Down 1.0%

NASDAQ KNSA traded down $0.31 during trading on Friday, reaching $30.06. The company's stock had a trading volume of 1,224,939 shares, compared to its average volume of 594,751. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of 751.69 and a beta of 0.05. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $31.92. The firm has a 50 day moving average price of $28.19 and a 200 day moving average price of $23.89.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.08%. On average, equities analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.